, and both were mRNA-based shots. The Oxford-AstraZeneca shot is in use around the world as well.
Connor defended GSK's response to the pandemic, expressing confidence in the partnerships GSK has forged with other vaccine developers likeand Sanofi. Those efforts may still deliver for the world, though later than initially hoped, he said. At the start of the pandemic, mRNA was an unproven platform, with no federally approved mRNA vaccines or medicines. A few months before the SARS-CoV-2 virus emerged in China, GSK's leaders had described technology like mRNA as being far from reality.
Scaling up manufacturing would be too complex, and the platform was still unproven, he said. The technology had yet to be tested in humans beyond a small pilot study of an experimental rabies vaccine, which influenced the decision. "On a personal level, it felt like it wasn't enough," they said."This was upending our lives, and I just wanted to know we were doing something about it."
"We call it a hemorrhage, and it's still ongoing," said one former scientist at the Maryland facility who recently left.
good
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.